BUDGET IMPACT ANALYSIS IN THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD
We have performed the first-ever Budget Impact Analysis (BIA) in a Russian context of bendamustine in the first line of therapy of a multiple myeloma for patients more senior 65 years old with clinical manifestations of a polineuropathy, which autological transplantation of stem cells isn't sho...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Kniha |
| Vydáno: |
IRBIS LLC,
2015-06-01T00:00:00Z.
|
| Témata: | |
| On-line přístup: | Connect to this object online. |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
Internet
Connect to this object online.3rd Floor Main Library
| Signatura: |
A1234.567 |
|---|---|
| Jednotka 1 | Dostupné |